EUVIMEDObjevte EUVIMED
ÜbersichtsarbeitOpen access · CC BY 4.0

Piperazine Derivatives: A Privileged Scaffold in Modern Synthesis and Medicinal Chemistry

Assel Ten, Raushan Koizhaiganova iD, Dilnaz Bissenbay, Bagila Tursynova, Zhanar Zhaxibayeva, Valentina Yu

ChemistryOpen · 2026-01 · 15 (1)

DOI: 10.1002/open.202500366 ↗

At a glance

Übersichtsarbeit in ChemistryOpen, published online on 2026-01-19. Written by Assel Ten and 5 co-authors. Institution: Laboratory of Synthetic and Natural Medicinal Compounds Chemistry, A.B. Bekturov Institute of Chemical Sciences, Almaty, Kazakhstan. Major MEDLINE topics: Piperazines, Piperazine. Cited 23 times so far (Crossref); 149 references. The full text is freely available (open access, CC BY 4.0). Funded by: Science Committee of the Ministry of Science and Higher Education of the Republic of Kazakhstan.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Interest in piperazine scaffolds continues to rise due to their broad relevance across anti‐infective, anticancer, and neuroactive research. This review examines reports published from 2014 to 2024 and organizes current developments by therapeutic class, structural modification strategy, and computational assessment. Substitution patterns involving aryl, heterocyclic, and hybrid groups show consistent effects on target affinity, selectivity, and pharmacokinetic properties. Several series demonstrate strong activity in early biological evaluation, supported by docking and pharmacodynamic trends that highlight recurring structural motifs. Synthetic approaches, including N ‐functionalization, reductive routes, cross‐coupling, CH activation, microwave‐assisted reactions, and flow‐based methods, provide diverse access to optimized derivatives. Combined interpretation of synthetic, biological, and computational results outlines reproducible structure–property relationships that guide piperazine‐focused design. Future progress is expected to arise from hybrid scaffold engineering, improved strategies for central nervous system delivery, and the integration of predictive machine‐learning methods into lead refinement.

Subjects

MeSH terms (MEDLINE)

PiperazinesPiperazineChemistry, PharmaceuticalHumansStructure-Activity RelationshipAnti-Infective AgentsAntineoplastic Agents

Author keywords

anticancer agentsantimicrobialsantipsychoticsheterocyclic synthesispiperazineprivileged scaffoldstructure–activity relationship

Substances

PiperazinesPiperazineAnti-Infective AgentsAntineoplastic Agents

Authors and institutions

  • Laboratory of Synthetic and Natural Medicinal Compounds Chemistry, A.B. Bekturov Institute of Chemical Sciences, Almaty, Kazakhstan.
  • Faculty of Chemistry, Al-Farabi Kazakh National University, Almaty, Kazakhstan.
  • Department of Chemistry, Kazakh National Pedagogical University named after Abai, Almaty, Kazakhstan.

ORCID profiles: Raushan Koizhaiganova

Funding

  • Science Committee of the Ministry of Science and Higher Education of the Republic of Kazakhstan

Cite

APA

Ten, A., Koizhaiganova, R., Bissenbay, D., Tursynova, B., Zhaxibayeva, Z., & Yu, V. (2026). Piperazine Derivatives: A Privileged Scaffold in Modern Synthesis and Medicinal Chemistry. ChemistryOpen, 15(1). https://doi.org/10.1002/open.202500366

Vancouver

Ten A, Koizhaiganova R, Bissenbay D, Tursynova B, Zhaxibayeva Z, Yu V. Piperazine Derivatives: A Privileged Scaffold in Modern Synthesis and Medicinal Chemistry. ChemistryOpen. 2026;15(1). doi:10.1002/open.202500366

BibTeX
@article{Ten2026,
  author = {Ten, Assel and Koizhaiganova, Raushan and Bissenbay, Dilnaz and Tursynova, Bagila and Zhaxibayeva, Zhanar and Yu, Valentina},
  title = {Piperazine Derivatives: A Privileged Scaffold in Modern Synthesis and Medicinal Chemistry},
  journal = {ChemistryOpen},
  year = {2026},
  volume = {15},
  number = {1},
  doi = {10.1002/open.202500366}
}
Start for free →